FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
615 Following 102.7K Followers
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing total lung capacity.
Show more
Matchpoint Therapeutics has aced its series B round, serving up $150 million to advance the Sanofi-backed biotech’s pipeline of precision covalent medicines.
Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an eye disease gene therapy, encouraging the biotech to forge ahead with a study that could support a filing for approval in 2028.
Show more
The Bay Area biotech is discontinuing all clinical development activities and implementing a "substantial reduction in workforce."
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest.
Show more
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
The 2026 Fierce 15 is here.
Meet the 15 private biotech companies our editors selected as some of the most promising in the industry. #Fierce15#
Genentech CEO talks Fierce through vision for the future
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28.
Show more
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates.
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months
Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.
Show more
Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
The Biomedical Advanced Research and Development Authority has awarded Scynexis with a $214 million contract for development of a treatment for invasive fungal infections.
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead Sciences.
Show more
Daiichi and Merck withdrew an ADC filing after the FDA said they lacked the data for accelerated approval in a lung cancer population. $MRK
